About Us
Transformational Innovation
Mission
Elixir Medical is committed to transforming care of patients with heart and vascular disease through innovation.
Since 2005, the company has continually sought to improve the treatment of vascular disease with:
- Drug-eluting coronary stent systems (DES)
- Fully resorbable drug-eluting scaffold systems (BRS)
- Drug-eluting coronary bioadaptor systems
Its latest innovation — the DynamX™ Coronary Bioadaptor System — is designed to be a significant advancement beyond drug-eluting stents (DES).
Elixir Medical’s innovations are designed to make a meaningful change in patients’ lives. The company does not simply want to engineer a better medical device. Saving lives and helping patients enjoy their daily life is what drives us every day.
Management Team

Motasim Sirhan
Vinayak Bhat, PhD
John Yan
Alaeddin Ahram
Richard Castro
Candace Elek
Howard Huang
Andrew Kramer
Alex Nepogodiev
Investors
Elixir Medical is a private company. Its lead investor is The Invus Group. The evergreen equity investment firm has over $8 billion under management and offices in New York, Paris and Hong Kong.
Invus has been a committed partner of Elixir Medical since it was founded. Invus invests in visionary entrepreneurial teams and empowers them to transform their industries by taking risks, building sustainable competitive advantage and maintaining a long-term perspective.